AstraZeneca PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NASDAQ | USD | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| OTC Markets | USD | Delayed | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
Among the 6 biggest deal dispatches this past week, Microsoft is reportedly in talks to invest billions in ChatGPT owner OpenAI. Here’s the full list, as covered in real time...
By Liz Moyer Investing.com -- Stocks were higher on Monday as fading fears about interest rates lifted tech shares. Here are the midday movers for Jan. 9. Lululemon Athletica...
This market has reached a once-in-two-year turning point. And it’s made our favorite income investments—closed-end funds (CEFs)—terrific contrarian...
Genome sequencing solutions company Illumina (NASDAQ:ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused shares to spiral down...
Cost of sequencing a single human genome has fallen from $100 million to $600 since 2001 Illumina’s new machines can further drop the cost to under $200 Illumina won an...
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
| Average | 76.67 (+10.87% Upside) |
| High | 88.00 |
| Low | 65.00 |
| Price | 69.15 |
| No. of Analysts | 6 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Neutral | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Buy |
| Summary | Neutral | Neutral | Strong Sell | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 133.42 | 133.51 | 127.35 | +6.25 | +4.91% | 137.60M | NASDAQ | |||
| 8.06 | 8.13 | 7.79 | -0.12 | -1.47% | 7.80M | NYSE | |||
| 99.28 | 99.42 | 95.91 | +5.37 | +5.72% | 53.17M | NASDAQ | |||
| 6.49 | 6.55 | 6.06 | +0.11 | +1.72% | 13.42M | NYSE | |||
| 139.37 | 139.94 | 134.61 | +3.22 | +2.37% | 28.53M | NASDAQ | |||
| 342.50 | 344.00 | 332.63 | +26.72 | +8.46% | 27.20M | NASDAQ | |||
| 240.22 | 240.74 | 234.51 | +8.29 | +3.57% | 34.98M | NASDAQ | |||
| 9.40 | 9.88 | 9.03 | +0.45 | +5.03% | 20.00M | NYSE | |||
| 4.03 | 4.36 | 3.93 | -0.140 | -3.36% | 1.20M | NASDAQ | |||
| 53.70 | 54.00 | 53.70 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 106.14 | 106.21 | 101.75 | +4.24 | +4.16% | 4.96M | NYSE | |||
| 93.08 | 93.17 | 90.61 | +1.28 | +1.39% | 1.05M | NYSE | |||
| 30.99 | 31.07 | 30.53 | +0.45 | +1.47% | 886.09K | NYSE | |||
| 46.78 | 46.83 | 45.67 | +0.32 | +0.69% | 21.79M | NASDAQ | |||
| 0.39 | 0.41 | 0.35 | +0.03 | +6.85% | 1.62M | NASDAQ |